Fairmount Funds Management Llc - Net Worth and Insider Trading
Fairmount Funds Management Llc Net Worth
The estimated net worth of Fairmount Funds Management Llc is at least $76 Million dollars as of 2024-05-09. Fairmount Funds Management Llc is the Director, 10% Owner of Dianthus Therapeutics Inc and owns about 1,903,833 shares of Dianthus Therapeutics Inc (DNTH) stock worth over $47 Million. Fairmount Funds Management Llc is also the See Remarks of Cogent Biosciences Inc and owns about 3,558,975 shares of Cogent Biosciences Inc (COGT) stock worth over $28 Million. Details can be seen in Fairmount Funds Management Llc's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Fairmount Funds Management Llc has not made any transactions after 2023-09-26 and currently still holds the listed stock(s).
Transaction Summary of Fairmount Funds Management Llc
Fairmount Funds Management Llc Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Fairmount Funds Management Llc owns 5 companies in total, including Cogent Biosciences Inc (COGT) , Viridian Therapeutics Inc (VRDN) , and Spyre Therapeutics Inc (SYRE) among others .
Click here to see the complete history of Fairmount Funds Management Llc’s form 4 insider trades.
Insider Ownership Summary of Fairmount Funds Management Llc
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| COGT | Cogent Biosciences Inc | 2023-06-09 | 10 percent owner & other: See Remarks |
| VRDN | Viridian Therapeutics Inc | 2020-10-27 | director & other: See Remarks |
| SYRE | Spyre Therapeutics Inc | 2023-06-22 | director & 10 percent owner |
 | | 2023-07-13 | director |
| | 2023-09-19 | director & 10 percent owner |
Fairmount Funds Management Llc Latest Holdings Summary
Fairmount Funds Management Llc currently owns a total of 2 stocks. Among these stocks, Fairmount Funds Management Llc owns 1,903,833 shares of Dianthus Therapeutics Inc (DNTH) as of September 26, 2023, with a value of $47 Million and a weighting of 62.74%. Fairmount Funds Management Llc also owns 3,558,975 shares of Cogent Biosciences Inc (COGT) as of June 9, 2023, with a value of $28 Million and a weighting of 37.26%.
Latest Holdings of Fairmount Funds Management Llc
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| DNTH | Dianthus Therapeutics Inc | 2023-09-26 | 1,903,833 | 24.93 | 47,462,557 |
| COGT | Cogent Biosciences Inc | 2023-06-09 | 3,558,975 | 7.92 | 28,187,082 |
Holding Weightings of Fairmount Funds Management Llc
Fairmount Funds Management Llc Form 4 Trading Tracker
According to the SEC Form 4 filings, Fairmount Funds Management Llc has made a total of 3 transactions in Dianthus Therapeutics Inc (DNTH) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Dianthus Therapeutics Inc is the acquisition of 30,000 shares on September 26, 2023, which cost Fairmount Funds Management Llc around $394,500.
According to the SEC Form 4 filings, Fairmount Funds Management Llc has made a total of 2 transactions in Cogent Biosciences Inc (COGT) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Cogent Biosciences Inc is the acquisition of 800,000 shares on June 9, 2023, which cost Fairmount Funds Management Llc around $10 Million.
Insider Trading History of Fairmount Funds Management Llc
- 1
Fairmount Funds Management Llc Trading Performance
GuruFocus tracks the stock performance after each of Fairmount Funds Management Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Fairmount Funds Management Llc is 1.47%. GuruFocus also compares Fairmount Funds Management Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Fairmount Funds Management Llc within 3 months outperforms 1 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Fairmount Funds Management Llc's insider trading performs compared to the benchmark.
Performance of Fairmount Funds Management Llc
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 4.55 | | | | | |
| Relative Return to S&P 500(%) | 5.03 | | | | | |
Fairmount Funds Management Llc Ownership Network
Fairmount Funds Management Llc Owned Company Details
What does Cogent Biosciences Inc do?
Who are the key executives at Cogent Biosciences Inc?
Fairmount Funds Management Llc is the 10 percent owner & other: See Remarks of Cogent Biosciences Inc. Other key executives at Cogent Biosciences Inc include Chief Legal Officer Evan Kearns , Chief Financial Officer John L. Green , and Chief Scientific Officer John Edward Robinson .
Cogent Biosciences Inc (COGT) Insider Trades Summary
Over the past 18 months, Fairmount Funds Management Llc made 1 insider transaction in Cogent Biosciences Inc (COGT) with a net purchase of 800,000.
In summary, during the past 3 months, insiders sold 0 shares of Cogent Biosciences Inc (COGT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cogent Biosciences Inc (COGT) were sold and 800,000 shares were bought by its insiders, resulting in a net purchase of 800,000 shares.
Cogent Biosciences Inc (COGT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cogent Biosciences Inc Insider Transactions
Fairmount Funds Management Llc Mailing Address
Above is the net worth, insider trading, and ownership report for Fairmount Funds Management Llc. You might contact Fairmount Funds Management Llc via mailing address: 200 Barr Harbor Drive, Suite 400, West Conshohocken Pa 19428.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
